MX389496B - Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac) - Google Patents

Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac)

Info

Publication number
MX389496B
MX389496B MX2019005934A MX2019005934A MX389496B MX 389496 B MX389496 B MX 389496B MX 2019005934 A MX2019005934 A MX 2019005934A MX 2019005934 A MX2019005934 A MX 2019005934A MX 389496 B MX389496 B MX 389496B
Authority
MX
Mexico
Prior art keywords
sup
enac
compounds
sodium channel
benzodiazolium
Prior art date
Application number
MX2019005934A
Other languages
English (en)
Spanish (es)
Other versions
MX2019005934A (es
Inventor
Clive Mccarthy
Duncan Alexander Hay
Jonathan David Hargrave
Naomi Went
Thomas Beauregard Schofield
Original Assignee
Enterprise Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterprise Therapeutics Ltd filed Critical Enterprise Therapeutics Ltd
Publication of MX2019005934A publication Critical patent/MX2019005934A/es
Publication of MX389496B publication Critical patent/MX389496B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2019005934A 2016-11-22 2017-11-22 Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac) MX389496B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619694.1A GB201619694D0 (en) 2016-11-22 2016-11-22 Compounds
PCT/GB2017/053499 WO2018096325A1 (en) 2016-11-22 2017-11-22 Benzodiazolium compounds as enac inhibitors

Publications (2)

Publication Number Publication Date
MX2019005934A MX2019005934A (es) 2019-11-12
MX389496B true MX389496B (es) 2025-03-20

Family

ID=57993838

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005934A MX389496B (es) 2016-11-22 2017-11-22 Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac)

Country Status (20)

Country Link
US (4) US10941149B2 (enExample)
EP (1) EP3544981B1 (enExample)
JP (1) JP6980014B2 (enExample)
KR (1) KR102517273B1 (enExample)
CN (1) CN110214141B (enExample)
AU (1) AU2017364308B2 (enExample)
CA (1) CA3043132A1 (enExample)
DK (1) DK3544981T3 (enExample)
EA (1) EA039607B1 (enExample)
ES (1) ES2890226T3 (enExample)
GB (1) GB201619694D0 (enExample)
HU (1) HUE055692T2 (enExample)
IL (1) IL266745B (enExample)
MA (1) MA46878A (enExample)
MX (1) MX389496B (enExample)
PL (1) PL3544981T3 (enExample)
PT (1) PT3544981T (enExample)
TW (1) TWI756305B (enExample)
WO (1) WO2018096325A1 (enExample)
ZA (1) ZA201902710B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) * 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
KR20220050126A (ko) 2019-06-12 2022-04-22 티엠이엠16에이 리미티드 호흡기 질환을 치료하기 위한 화합물
GB201908453D0 (en) 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease
GB201910608D0 (en) * 2019-07-24 2019-09-04 Enterprise Therapeutics Ltd Compounds
TW202237090A (zh) 2020-12-11 2022-10-01 英商Tmem16A有限公司 治療呼吸道疾病之化合物
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
GB202406247D0 (en) 2024-05-03 2024-06-19 Enterprise Therapeutics Ltd Compounds and pharmaceutical compositions

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
US6903105B2 (en) 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
US20050090505A1 (en) 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
AU2004266704B2 (en) 2003-08-18 2012-02-23 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
EP1670474A4 (en) 2003-08-18 2008-08-06 Parion Sciences Inc CYCLIC PYRAZINOYLGUANIDINE AS SODIUM CHANNEL BLOCKER
CA2534568A1 (en) 2003-08-18 2005-03-24 Parion Sciences, Inc. Aliphatic pyrazinoylguanidine sodium channel blockers
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
WO2005042497A2 (en) * 2003-10-28 2005-05-12 Vertex Pharmaceuticals, Incorporated Benzimidazoles useful as modulators of ion channels
US7399766B2 (en) 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
US20060223849A1 (en) * 2005-03-14 2006-10-05 Mjalli Adnan M Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
US7807834B2 (en) 2005-08-03 2010-10-05 Parion Sciences, Inc. Capped pyrazinoylguanidine sodium channel blockers
GB0526240D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US8288391B2 (en) 2007-04-03 2012-10-16 Parion Sciences, Inc. Pyrazinoylguanidine compounds for use as taste modulators
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
WO2009139948A1 (en) 2008-02-26 2009-11-19 Johnson Michael R Poly aromatic sodium channel blockers
MX2010012441A (es) 2008-05-13 2010-12-06 Novartis Ag Derivados de acido 3,5-diamino-6-cloro-pirazin-2-carboxilico y su uso como bloqueadores del canal de sodio epitelial para el tratamiento de enfermedades de las vias respiratorias.
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
WO2011028740A1 (en) 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
WO2011079087A1 (en) 2009-12-23 2011-06-30 Glaxo Group Limited Enac blockers
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
TW201204353A (en) * 2010-06-08 2012-02-01 Vertex Pharma Formulations of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
NO2773633T3 (enExample) 2011-11-02 2017-12-30
US8859559B2 (en) 2011-12-20 2014-10-14 Boehringer Ingelheim International Gmbh Substituted pyrazines and their use in the treatment of disease
WO2013181232A2 (en) 2012-05-29 2013-12-05 Michael Ross Johnson Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
WO2014044849A1 (en) 2012-09-24 2014-03-27 Boehringer Ingelheim International Gmbh Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
EP2991981B1 (en) 2013-04-30 2017-03-01 Boehringer Ingelheim International GmbH Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
CA2915633A1 (en) 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
WO2015003958A1 (en) 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
WO2015007519A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel benzimidazolium compounds
EP3022197B1 (en) 2013-07-15 2017-09-06 Boehringer Ingelheim International GmbH Novel tetra- and pentasubstituted benzimidazolium compounds
WO2015007516A1 (en) 2013-07-15 2015-01-22 Boehringer Ingelheim International Gmbh Novel 5-substituted benzimidazolium compounds
EP3030555B1 (en) 2013-08-08 2019-01-30 Boehringer Ingelheim International GmbH Novel pyrazine amide compounds
US9932324B2 (en) 2015-01-12 2018-04-03 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
US10155749B2 (en) * 2015-01-12 2018-12-18 Boehringer Ingelheim International Gmbh Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
EP3245200B1 (en) 2015-01-12 2021-03-10 Boehringer Ingelheim International GmbH 2-(pyrazin-2-ylcarbonylaminomethyl)benzimidazolium compounds as epithelial sodium channel inhibitors
EP3245202B1 (en) 2015-01-12 2020-03-11 Boehringer Ingelheim International GmbH Tetrasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
MX2018002006A (es) 2015-08-20 2018-06-19 Boehringer Ingelheim Int Benzamidas apareadas novedosas.
EP3298022B1 (en) 2015-08-20 2019-06-05 Boehringer Ingelheim International GmbH Novel annelated phenoxyacetamides
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
AU2017364308A1 (en) 2019-05-23
US20210147432A1 (en) 2021-05-20
MA46878A (fr) 2019-10-02
CN110214141B (zh) 2022-05-31
US10941149B2 (en) 2021-03-09
KR102517273B1 (ko) 2023-04-03
US12371436B2 (en) 2025-07-29
BR112019009864A2 (pt) 2019-08-27
HUE055692T2 (hu) 2021-12-28
AU2017364308B2 (en) 2021-03-11
US20190315757A1 (en) 2019-10-17
MX2019005934A (es) 2019-11-12
US11739094B2 (en) 2023-08-29
EA039607B1 (ru) 2022-02-16
PL3544981T3 (pl) 2021-12-20
ZA201902710B (en) 2021-10-27
US20250304590A1 (en) 2025-10-02
DK3544981T3 (da) 2021-09-20
NZ753048A (en) 2024-09-27
US20240067653A1 (en) 2024-02-29
TWI756305B (zh) 2022-03-01
JP2019535747A (ja) 2019-12-12
CA3043132A1 (en) 2018-05-31
IL266745B (en) 2021-12-01
ES2890226T3 (es) 2022-01-18
GB201619694D0 (en) 2017-01-04
CN110214141A (zh) 2019-09-06
WO2018096325A1 (en) 2018-05-31
JP6980014B2 (ja) 2021-12-15
TW201833111A (zh) 2018-09-16
PT3544981T (pt) 2021-09-23
EP3544981B1 (en) 2021-06-23
IL266745A (en) 2019-07-31
EA201991253A1 (ru) 2019-11-29
EP3544981A1 (en) 2019-10-02
KR20190084076A (ko) 2019-07-15

Similar Documents

Publication Publication Date Title
MX2019005934A (es) Compuestos de benzodiazolio como inhibidores del canal de sodio epitelial (enac).
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
MX2020007265A (es) Derivados de rapamicina.
MX2023005636A (es) Inhibidores de bcl6 derivados de bencimidazolona.
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CY1123059T1 (el) Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX389513B (es) Compuestos heterocíclicos como inmunomoduladores.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
MX379459B (es) Inhibidores de bromodominios.
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MX379264B (es) Profarmacos de amidas de piridona utiles como moduladores de canales de sodio.
CU24564B1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
MY171945A (en) Compositions, formulations and methods for treating ocular diseases
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
EA201891644A1 (ru) Антибактериальные соединения и их применение
MX392259B (es) ANILLOS 6-5 FUSIONADOS COMO INHIBIDORES C5a
EA201990400A1 (ru) Соединения и композиции и их применение
MX387443B (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
CR20200214A (es) ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции